Patients with hepatocellular carcinoma(HCC)have poor long-term survival following curative resection because of the high rate of tumor early recurrence.Little is known about the trajectory of genomic evolution from pr...Patients with hepatocellular carcinoma(HCC)have poor long-term survival following curative resection because of the high rate of tumor early recurrence.Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC.In this study,we performed whole-genome sequencing(WGS)on 40 pairs of primary and early-recurrent hepatitis B virus(HBV)-related HCC tumors from patients who received curative resection,and from four patients whose primary and recurrent tumor were extensively sampled.We identified two recurrence patterns:de novo recurrence(18/40),which developed genetically independently of the primary tumor and carried different HCC drivers,and ancestral recurrence(22/40),which was clonally related to the primary tumor and progressed more rapidly than de novo recurrence.We found that the recurrence location was predictive of the recurrence pattern:distant recurrence tended to display the de novo pattern,whereas local recurrence tended to display the ancestral pattern.We then uncovered the evolutionary trajectories based on the subclonal architecture,driver-gene mutations,and mutational processes observed in the primary and recurrent tumors.Multi-region WGS demonstrated spatiotemporal heterogeneity and polyclonal,monophyletic dissemination in HCC ancestral recurrence.In addition,we identified recurrence-specific mutations and copy-number gains in BCL9,leading to WNT/β-catenin signaling activation and an immuneexcluded tumor microenvironment,which suggests that BCL9 might serve as a new therapeutic target for recurrent HCC.Collectively,our results allow us to view with unprecedented clarity the genomic evolution during HBV-related HCC early recurrence,providing an important molecular foundation for enhanced understanding of HCC with implications for personalized therapy to improve patient survival.展开更多
基金This study was jointly supported by the National Key R&D Program of China(No.2019YFC1315800,2019YFC1315802,2018YFA0109400)the National Natural Science Foundation of China(No.81830102,No.81772578,No.82173260+4 种基金No.81972708,No.82073123,No.81773069,No.82072681,No.82003082)Shanghai Technical Standard Program(21DZ2201100)Shanghai Rising-Star Program(18QA1401200)Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai(2018YQ14)Original Scientific Personalized Support Project of Fudan University(IDF152064/015).
文摘Patients with hepatocellular carcinoma(HCC)have poor long-term survival following curative resection because of the high rate of tumor early recurrence.Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC.In this study,we performed whole-genome sequencing(WGS)on 40 pairs of primary and early-recurrent hepatitis B virus(HBV)-related HCC tumors from patients who received curative resection,and from four patients whose primary and recurrent tumor were extensively sampled.We identified two recurrence patterns:de novo recurrence(18/40),which developed genetically independently of the primary tumor and carried different HCC drivers,and ancestral recurrence(22/40),which was clonally related to the primary tumor and progressed more rapidly than de novo recurrence.We found that the recurrence location was predictive of the recurrence pattern:distant recurrence tended to display the de novo pattern,whereas local recurrence tended to display the ancestral pattern.We then uncovered the evolutionary trajectories based on the subclonal architecture,driver-gene mutations,and mutational processes observed in the primary and recurrent tumors.Multi-region WGS demonstrated spatiotemporal heterogeneity and polyclonal,monophyletic dissemination in HCC ancestral recurrence.In addition,we identified recurrence-specific mutations and copy-number gains in BCL9,leading to WNT/β-catenin signaling activation and an immuneexcluded tumor microenvironment,which suggests that BCL9 might serve as a new therapeutic target for recurrent HCC.Collectively,our results allow us to view with unprecedented clarity the genomic evolution during HBV-related HCC early recurrence,providing an important molecular foundation for enhanced understanding of HCC with implications for personalized therapy to improve patient survival.